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INTRODUCTION
Hepatocellular carcinoma is the fifth most common neoplasm and the third leading cause of cancer-related mortality worldwide [1] . HCC carries a dismal prognosis, potentially curative surgery being possible only in the subset of patients diagnosed at the early stages of the disease. Although some responses are seen with conventional and targeted chemotherapies, their impact on overall survival is modest. For this reason, a more complete understanding of the molecular mechanisms involved in HCC development could have a significant influence on improving therapeutic strategies for this pathology [2] .
Recently, landmark studies have implicated the Hippo signaling pathway in the pathogenesis of HCC [3] [4] [5] . First identified in Drosophila, this pathway has emerged as an evolutionarily conserved mechanism that restricts organ size in different species. In mammals, this organ size regulator comprises several tumor suppressors (Mst1/2, Sav1/WW45, Lats1/2 and Mob1), acting in a kinase cascade that culminates in the phosphorylation and inactivation of the transcriptional co-activator YAP. On the contrary, uninhibited YAP localizes in the nucleus where it serves as a co-activator for the TEAdomain family member (TEAD) group of DNA-binding transcription factors. The YAP/TEAD complex promotes proliferative and survival programs by inducing the expression of target genes [4] [5] [6] . Notably, both the transgenic overexpression of YAP in mice [3, 7] and the liver-specific knockout of Mst1/2 or Sav1 [8] [9] [10] [11] expanded the liver size and ultimately induced HCC, revealing a significant role for the Hippo pathway in regulating organ size and tumorigenesis in mammals. In humans, amplification of the chromosomal region containing the YAP gene (11q22) has been reported in several tumor types [12] .
Consistent with these findings, the comprehensive survey of the most common solid cancer types revealed elevated YAP protein levels and nuclear localization in multiple human cancers, including HCC, cholangiocarcinoma (CC) and hepatoblastoma (HB) [5, 13] . Furthermore, clinical studies showed that YAP was an independent prognostic marker for overall survival and disease-free survival for HCC patients and that it was associated with tumor differentiation [14] .
Interestingly, the mammalian Hippo pathway is required to repress the activation of facultative adult liver stem cells, known as oval cells [15] . In normal adult liver, oval cells progenitors are localized in biliary ductules (canals of Hering) and are bipotential. Although hepatic oval cells are not commonly observed in physiological conditions, they can be isolated from liver following certain types of injury, such as treatments in which hepatocytes are unable to proliferate in response to toxic damage (e.g. treatment with 3,5-5 diethoxycarbonyl-1,4-dihydrocollidine or choline-deficient diets and ethionine (16) (17) (18) . Oval cell homeostasis is regulated by the Hippo pathway, as Mst1/2 or Sav1 ablation in mouse liver resulted in abundant oval cell accumulation [9, 11] .
A well-known protocol that induces a rapid expansion of the oval cell population is the Resistant-Hepatocyte (R-H) rat model [19] . In this model, the need to regain parenchymal cell mass after 2/3 partial hepatectomy (PH) leads to the rapid expansion of preneoplastic hepatocytes and oval cells, since proliferation of normal hepatocytes is completely inhibited by 2-acetylaminofluorene (2-AAF). Therefore, the advantage of this model is that it allows to investigate not only the evolution of the early preneoplastic lesions to fully developed HCCs, but also the expansion of oval cells.
Since the Hippo signaling pathway holds great promise in liver cancer therapy, but no information are available on the stage (early or late) at which it may play a critical role, the aim of the present study was to investigate the role of the Hippo-YAP pathway in the early stages of HCC development and in oval cell proliferation. Moreover, we also wanted to investigate if pharmacological YAP inhibition could impact on the hepatocarcinogenic process.
MATERIALS AND METHODS

Animals and Treatment
Guidelines for Care and Use of Laboratory Animals were followed during the investigation.
All animal procedures were approved by the Ethical Commission of the University of Cagliari and the Italian Ministry of Health. Male Fischer F-344 rats (100-125g) were purchased from Charles River (Milan, Italy).
R-H Protocol:
Rats injected intraperitoneally with diethylnitrosamine (DENA, 150 mg/kg body weight, Sigma-Aldrich, Milan, Italy) were subjected to the R-H model (for details, see Supporting Material). Animals were sacrificed 7 days after surgery (4 weeks after DENA) or 10 weeks and 14 months thereafter. The number of preneoplastic foci positive for the placental form of glutathione S-transferase (GSTP) was determined as previously described [20] . To investigate the effect of verterporfin (VP) (CAS number: 129497-78-5; USP Reference Standards) on early preneoplastic foci and oval cells, F-344 rats were exposed to the R-H protocol. VP was administered intraperitoneally (100 mg/kg) 1 hour prior to-and 3 and 5 days after PH. Animals were sacrificed 7 days after surgery.
6
CMD protocol: Four week-old male F-344 rats were initiated with DENA (150 mg/kg) and 2 weeks later fed a choline-methionine deficient (CMD) [21] diet for 4 months. 
Immunohistochemistry
Immediately after sacrifice, liver sections were fixed in 10% formalin or snap-frozen in liquid nitrogen. For details see Supp. Material.
Laser-capture Micro-dissection (LMD)
We microdissected 400 foci (1 week after PH), 20 nodules (10 weeks after initiation with DENA), and 9 HCCs (14 months), and random areas of surrounding GSTP-negative hepatocytes. Oval cells were also microdissected 1 week after PH. Microdissection was performed according to [22] (for details see Supp. Material).
qRT-PCR analysis
RNA was retro-transcribed using the High Capacity Kit (Life Technology). Analysis of YAP, β-TRCP, Birc-5, Ccnd1, c-myc, Gpc3 and Spp1 was performed using specific TaqMan probes (Life Technology) and GAPDH as endogenous control.
Cell lines
Human HCC cell lines, MLP29 mouse oval cells and RH rat cell lines were cultured as described in Supp. Material. Transduction of cells was performed as described in [23] .
Clinical features and histopathological diagnosis
For clinical features and histopathological diagnosis of 28 liver samples, see 
RESULTS
YAP accumulates in early preneoplastic lesions and oval cells.
To investigate whether derangement of the Hippo pathway is an early event in hepatocarcinogenesis, we used the Resistant-Hepatocyte (R-H) rat model [19] . This model is characterized by a synchronous expansion of carcinogen-initiated cells that can be easily identified by preneoplastic markers as early as 7 days after PH. Unlike normal 7 hepatocytes, preneoplastic hepatocytes and oval cells, are capable to divide after 2/3 PH, in the presence of the cytostatic environment generated by 2-AAF. This experimental model thus offers the advantage of studying the carcinogenic process from its very initial steps. As seen in Fig. 1A , immunohistochemistry of more than 300 foci, performed on serial liver sections 7 days after PH, showed that all the hepatocyte foci positive for the preneoplastic marker GSTP, were also homogeneously positive for YAP and its phosphorylated form (pYAP). Thus, YAP represents an extremely sensitive marker of preneoplastic stages. As already described in the original work (19) , a massive expansion of oval cells (identified by their morphological feature and by positivity to GGT, and GSTP, data not shown) was observed. Notably, while YAP positivity was also detected in the vast majority of proliferating oval cells, an almost negligible YAP staining could be observed in the surrounding hepatocytes (Fig. 1B) . YAP staining was also observed at later stages, namely 10 weeks (a time when nodules shared histomorphological characteristic with human dysplastic nodules) [24] , ( YAP cytoplasmic accumulation is associated to down-regulation of β β β β-TRCP.
To investigate whether YAP protein overexpression was paralleled by augmented mRNA levels, we performed qRT-PCR analyses on microdissected early preneoplastic foci and HCCs. As shown in Fig. 1E , no increase of YAP mRNA was detected at any of the time points examined. Since the increase of the YAP protein was not mediated by transcriptional mechanisms, we wondered if the observed increased level of YAP protein could be due to impaired protein degradation. Indeed, preneoplastic foci exhibited a marked down-regulation of the β-TRCP E3 ligase, known to mediate YAP degradation [25] ( Fig. 1F) .
miR-375 is downregulated in YAP-overexpressing preneoplastic nodules and HCCs. 8 MiR-375, that is down-regulated in human HCCs [26] and in a YAP overexpressing mouse model of liver chemical carcinogenesis [27] , regulates YAP expression and impairs HCC cells tumorigenic properties [26] . To investigate whether miR-375 down-regulation parallels YAP increase in early lesions, we performed a RT-PCR in 10 dysplastic nodules.
MiR-375 was significantly down-regulated in preneoplastic lesions (P< 0.01) (Fig. 1G) ,
suggesting that it can contribute to YAP increase at early stages of liver tumorigenesis.
Notably, down-regulation of miR-375 was maintained in HCCs as well, suggesting its relevant role in HCC development (Fig. 1H) .
YAP target genes are up-regulated in very early preneoplastic foci and in oval cells.
As shown by IHC (Fig. 1) , YAP was overexpressed in the cytoplasm of highly proliferating cells (preneoplastic hepatocytes and oval cells) and barely detectable in the nuclei. Since it is possible that a relatively small increase of nuclear YAP cannot be detectable by IHC
(similar to what observed for β-catenin in mouse liver adenomas where, in spite of activating mutations of the gene, cytoplasmic, but not nuclear staining was reported [28] , we directly investigated YAP transcriptional activation by measuring the expression of its target genes. Microarray analysis of YAP target genes performed in microdissected foci generated 7 days after PH showed that most of the previously identified YAP target genes [29] were up-regulated in early lesions compared to the surrounding non-preneoplastic liver (Supp. Fig. 2A ). qRT-PCR performed to validate some of these genes and to investigate the expression of other YAP target genes not present in the array is shown in Supp. Fig. 2B . A high expression of YAP-target genes was observed in microdissected oval cells (Supp. Fig. 2C ).
YAP accumulation at early stages of hepatocarcinogenesis is not restricted to the R-H model.
To investigate whether YAP accumulation is an event unique to the R-H model of hepatocarcinogenesis, we studied a different rat model consisting of a choline-devoid methionine-deficient diet [21] , and characterized by extensive fatty liver. IHC analysis showed a strong YAP accumulation in preneoplastic lesions (Supp. Fig. 3 ), suggesting that an early increase of YAP is a common event in multistage hepatocarcinogenesis.
The TEAD-YAP binding disruptor Verterporfin inhibits the growth of preneoplastic foci and oval cell proliferation. ; P<0.01) (Fig. 2A,B) .
Resection of 2/3 of the liver in the presence of the cytostatic environment generated by 2-AAF causes a massive expansion of oval cells, expressing markers specific for biliary epithelial cells (for example . While oval cells observed in DENA-AAF-PH-treated animals strongly expressed KTR-19, KRT-19 immunoreactivity in VP treated rats was restricted to bile ductular epithelial cells, thus demonstrating the complete inhibitory effect of VP on infiltration of liver parenchyma by oval cells (Fig. 2C) . This suggests that YAP-TEAD interaction is an absolute requirement for the proliferation of this progenitor cell compartment.
VP-mediated YAP inhibition impairs viability of HCCs and oval cells.
To further investigate the effect of VP, in vitro experiments were performed on Huh7 HCC cells transduced with YAP (Supp. Fig. 4A ) or the empty vector. As shown in Fig. 2D , VP impaired the growth of control Huh7 cells, while a much weaker effect was observed on cells transduced with YAP, suggesting that high levels of YAP protect cells from VP. VP also impaired both the viability and the colony forming ability of rat tumorigenic cells derived from HCCs generated by the R-H model (Supp. Fig. 4B-C) .
The effect of VP was evaluated in oval cells as well. To mimic the physiological stimuli present in a damaged liver, we treated mouse oval cells (MLP29), with Hepatocyte Growth Factor (HGF), known to stimulate their growth. As shown in Fig. 2E , VP inhibited HGFinduced proliferation.
YAP overexpression confers tumorigenic and metastatic properties to oval cells.
The Hippo signaling pathway plays a pivotal role in regulating oval cells, putative liver cancer progenitor cells [15] . As oval cells in the livers of R-H rats are positive for YAP (Fig   1B) , we investigated the effect of YAP overexpression in MLP29 cells. Fig. 4D ). As shown in Fig.   3A , YAP WT overexpressing MLP29 cells acquired the ability to grow in anchorageindependent conditions; the effect was significantly stronger in cells overexpressing active
YAP (YAP SS).
To test their tumorigenic ability, we subcutaneously inoculated MLP29 cells in nude mice.
Tumors generated by MLP29 YAP WT and MLP YAP SS cells were bigger than those of MLP29 control cells (Fig. 3B) . Moreover, mice inoculated with MLP29 YAP WT or MLP29
YAP SS presented several and large lung metastases (Fig. 3C) ; the number and the size of metastases was significantly higher in mice inoculated with MLP29 YAP SS cells ( Fig   3D) . All together these data suggest that YAP overexpression promotes the tumorigenic and metastatic properties of oval cells.
VP inhibits nuclear receptor-mediated hepatomegaly.
A recent study on transgenic mice reported that while YAP-TEAD interaction is dispensable for the achievement of normal liver size, it is required for organ overgrowth [29] . To examine whether this mechanism is operating also in genetically unmodified animals, we induced liver hyperplasia by the powerful liver mitogen TCPOBOP, a ligand of the constitutive androstane receptor (CAR). In agreement with our previous reports [27] , a single treatment with TCPOBOP induced hepatomegaly within 3 days, which was associated with a striking increase of hepatocyte proliferation (Supp. Fig. 5A-C) . Nuclear translocation of YAP was often observed in hepatocytes from the hyperplastic liver. (Supp.
Fig. 5D).
Treatment with VP reduced TCPOBOP-induced hepatomegaly, strongly impaired hepatocyte proliferation (Supp. Fig. 5A-C) , and decreased the number of hepatocyte nuclei positively stained for YAP (Supp. Fig. 5D) . Similarly, the expression of the YAP target Birc-5 was poorly induced after TCPOBOP+VP treatment versus TCPOBOP alone, indicating decreased activation of YAP (Supp. Fig. 6 ).
YAP accumulation in human hepatic tumorigenesis
To investigate at which stage YAP accumulation takes place in human hepatic tumorigenesis, we examined its expression in early dysplastic nodules ( Table 1) . YAP immunoreactivity was negligible in the cirrhotic parenchyma, but visible in early dysplastic lesions, as isolated cells or sporadic clusters (Fig. 4A-C) . YAP immunoreactivity increased from early HCC to advanced HCC, the highest expression being in poorly differentiated 11 HCC (Supp. Fig. 7A-C) . Cholangiocarcinomas (Supp. Fig. 7A-C) . However, the small number of investigated cases did not allow drawing definitive conclusions.
We also examined neoplastic progression in the so-called healthy liver, whereby hepatocellular adenomas are associated or not with HCC development (Table 1, Fig. 4) .
YAP immunoreactivity was seen in different varieties of adenomas such as the β-cateninactivated ( Fig. 4D-F) , steatotic (or HNF-α mutated) (Fig. 4G-I) , and telangiectatic/inflammatory (Fig. 4L-N) subtypes, with abrupt disappearance in the adjacent non-neoplastic liver. YAP expression varied from 10 to 80% of neoplastic cells, and the pattern of staining was mostly cytoplasmic, diffuse or granular (Fig. 4C,F,I ,N), with occasional nuclear accumulation (Fig. 4F) . In HCC arising in the context of an adenoma ( 
DISCUSSION
Recent studies, both in Drosophila and mammals, have implicated the Hippo signaling pathway as a potent regulator of organ size and tissue homeostasis. Indeed, studies from different groups employing genetically modified animals showed that the overexpression of YAP and the combined Mst1/2 deficiency lead to massive liver overgrowth and development of HCC [7] [8] . Notably, Mst1/2 or Sav ablation in mouse liver originated mixed HCC and cholangiocarcinomas and resulted also in oval cell accumulation [9, 11] . Later on, more strength to the critical role of dysregulation of the Hippo pathway in liver cancer development has come from the finding of its widespread involvement in human cancer [13] , including HCC and CC, suggesting that this pathway might be an attractive therapeutic target.
Our study demonstrates that the expression of YAP is increased in very early preneoplastic hepatocyte foci in two non-transgenic models of hepatocarcinogenesis.
These results strongly support the notion that the inactivation of the Hippo pathway allows genetically damaged cells to evade the intrinsic size-control mechanisms that normally 
